Profile data is unavailable for this security.
About the company
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-87.98m
- Incorporated2019
- Employees163.00
- LocationLianBio103 Carnegie Center DriveSuite 309, Suite 215PRINCETON 08540United StatesUSA
- Phone+1 (609) 486-2308
- Websitehttps://www.lianbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ImmuCell Corp | 23.22m | -4.05m | 28.67m | 74.00 | -- | 1.22 | -- | 1.23 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Curis Inc | 10.16m | -47.57m | 29.95m | 48.00 | -- | -- | -- | 2.95 | -8.24 | -8.24 | 1.76 | -0.1175 | 0.1509 | -- | 4.12 | 211,687.50 | -70.62 | -37.25 | -90.04 | -41.12 | 98.30 | 96.05 | -468.18 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Quince Therapeutics Inc | 0.00 | -53.12m | 30.29m | 32.00 | -- | 0.645 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
Elevation Oncology Inc | 0.00 | -39.70m | 30.88m | 29.00 | -- | 0.3528 | -- | -- | -0.8399 | -0.8399 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -35.30 | -- | -37.14 | -- | -- | -- | -- | -- | -- | -25.25 | 0.2765 | -- | -- | -- | 51.93 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -64.66m | 31.04m | 41.00 | -- | 0.3154 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Lumos Pharma Inc | 1.49m | -35.75m | 31.28m | 33.00 | -- | 3.04 | -- | 21.05 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 31.42m | 163.00 | -- | 0.154 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Ocean Biomedical Inc | 0.00 | -98.59m | 31.57m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
FibroGen Inc | 173.82m | -168.32m | 32.97m | 486.00 | -- | -- | -- | 0.1897 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 33.06m | 73.00 | -- | 0.9894 | -- | 14.03 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -7.31m | 33.54m | -- | -- | 7.87 | -- | -- | -0.1977 | -0.1977 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -195.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 33.95m | 4.00 | -- | 9.75 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Unicycive Therapeutics Inc | 0.00 | -24.41m | 33.96m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Perceptive Advisors LLCas of 29 Feb 2024 | 57.56m | 53.26% |
RhumbLine Advisers LPas of 30 Jun 2024 | 147.72k | 0.14% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 14.62k | 0.01% |
FNY Capital Management LPas of 30 Jun 2024 | 13.80k | 0.01% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
Anson Funds Management LPas of 31 Mar 2024 | 0.00 | 0.00% |
Casdin Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Myda Advisors LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Cubist Systematic Strategies LLCas of 31 Mar 2024 | 0.00 | 0.00% |